source
- Roivant's experimental pulmonary hypertension drug meets Phase 2 goalsRoivant announced that its experimental drug mosliciguat achieved the primary endpoint in a 16‑week Phase 2 trial for pulmonary hypertension, a serious lung condition. The study showed a 56% reduc…
- Novartis' Lp(a) drug pelacarsen fails to cut heart attack or stroke risk in phase 3 trialNovartis, in partnership with Ionis, completed the phase 3 Lp(a)Horizon trial of pelacarsen, an antisense oligonucleotide designed to lower lipoprotein(a) levels. The study enrolled more than 8,30…